| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: ≥98%
Diatrizoate Sodium is an X-ray contrast agent. By obstructing X-rays, the diatrizoate sodium drug enables the differentiation between iodine-containing and iodine-free body structures. Radiography, angiography, and urography all use this as a diagnostic tool.
| ln Vitro |
For two to twenty-four hours, HK-2 cells were treated to either a vehicle or 0–30 mg I/mL sodium diatrizoate (sodium diatrizoate salt). According to the MTT and trypan blue exclusion experiments, cell viability and mitochondrial content drop after two and twenty-four hours, respectively [2].
|
|---|---|
| ln Vivo |
Sodium diatrizoate is an iodinated radiographic contrast agent. After insufflation of sodium diatrizoate nanoparticle aggregates, histological analysis of rat lung tissue revealed no acute toxicity or inflammation. Sodium diatrizoate nanoparticle agglomerates present a promising alternative for safe and efficient lung visualization [1].
|
| Animal Protocol |
To assess acute lung toxicity, female Sprague-Dawley rats (200-250 g) were anesthetized with a subcutaneous cocktail of ketamine (67.5 mg/kg), xylazine (3.5 mg/kg), and acepromazine (0.66 mg/kg). While under anesthesia and placed on a heating pad, **diatrizoate sodium** nanoparticle agglomerate dry powder (10 mg) was administered via intratracheal insufflation using a dry powder insufflator with 3 mL of air. Two hours post-insufflation, rats were euthanized by isoflurane inhalation overdose, and lungs were harvested for histological examination. [1]
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Radioactive iodine is excreted into human milk during lactation. It is currently unclear whether GLOFIL-125 is excreted into human milk. Sodium iodate has a renal clearance rate in humans very close to that of inulin. This compound is cleared by glomerular filtration and is not secreted or reabsorbed by the renal tubules. Biological Half-Life The effective half-life after infusion of iodine-125 iodate is approximately 0.07 days. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Medication Use During Lactation Very little iodine contrast agents injected intravenously are excreted into breast milk, and their oral absorption rate is also very low. Therefore, they are unlikely to enter the infant's bloodstream and will not cause any adverse effects on breastfed infants. Guidelines developed by multiple professional organizations indicate that breastfeeding mothers do not need to interrupt breastfeeding after receiving iodine-containing contrast agents. However, since there is currently no published experience regarding the use of iostatin during lactation, other medications may be preferred, especially when breastfeeding newborns or premature infants. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Non-human toxicity values Rat intravenous LD50: 14,700 mg/kg Mouse intramuscular LD50: 20,349 mg/kg Mouse intravenous LD50: 1400 mg/kg Cat intravenous LD50: 11,300 mg/kg Dog intravenous LD50: 13,200 mg/kg |
| References | |
| Additional Infomation |
Sodium amidotrizoate is the sodium salt of benzoic acid, with iodine substituents at positions 2, 4, and 6, and acetamido substituents at positions 3 and 5. It is often used in combination with meglumine salt as an X-ray contrast agent for gastrointestinal examinations, angiography, and urography. It is a radiopaque contrast agent. It is an organic iodine compound and an organic sodium salt containing the sodium amidotrizoate anion.
Sodium diiodoformate is an iodinated radiopaque X-ray contrast agent. Sodium diiodoformate blocks X-rays, thus contrasting iodine-containing surface structures with iodine-free surface structures, making these areas clearly visible. This contrast agent can be used as an adjunct diagnostic agent in angiography, urography, and radiography. (NCI05) See also: diiodobenzoic acid (with active moiety); diiodobenzoic acid meglumine; diiodotrazolium sodium (component). Therapeutic Use GLOFIL-125 (sodium iostatin injection) is indicated for the diagnosis or monitoring of patients with kidney disease to assess glomerular filtration rate.Drug Warnings Contrast AgentsAs with any radioactive material, care should be taken to minimize radiation exposure for patients under appropriate patient management and to ensure that radiation exposure for occupational workers is kept to a minimum. Rapid or bolus injections should be avoided. Radiopharmaceuticals should only be administered by qualified physicians who are trained and have experience in the safe use and handling of radionuclides. For more complete data on drug warnings for iostatin (out of 8), please visit the HSDB records page. |
| Molecular Formula |
C11H8I3N2NAO4
|
|---|---|
| Molecular Weight |
635.89
|
| Exact Mass |
635.751
|
| Elemental Analysis |
C, 20.78; H, 1.27; I, 59.87; N, 4.41; Na, 3.62; O, 10.06
|
| CAS # |
737-31-5
|
| Related CAS # |
Diatrizoic acid;117-96-4
|
| PubChem CID |
23672589
|
| Appearance |
Rhombic needles
White crystals |
| Boiling Point |
614.1ºC at 760 mmHg
|
| Melting Point |
261-262 °C (decomposes)
|
| Flash Point |
325.2ºC
|
| LogP |
1.926
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
396
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
IC1C(=C(C(C(=O)[O-])=C(C=1N([H])C(C([H])([H])[H])=O)I)I)N([H])C(C([H])([H])[H])=O.[Na+]
|
| InChi Key |
ZEYOIOAKZLALAP-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1
|
| Chemical Name |
sodium;3,5-diacetamido-2,4,6-triiodobenzoate
|
| Synonyms |
Diatrizoate sodium; Hypaque; MD-50; MD50; MD 50; Urovist Sodium; Triombrin
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~157.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 33.33 mg/mL (52.41 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5726 mL | 7.8630 mL | 15.7260 mL | |
| 5 mM | 0.3145 mL | 1.5726 mL | 3.1452 mL | |
| 10 mM | 0.1573 mL | 0.7863 mL | 1.5726 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03573921 | Recruiting | Drug: Gastrografin Other: Saline solution (control treatment) |
Small Bowel Obstruction | Lawson Health Research Institute | September 1, 2019 | Phase 2 Phase 3 |
| NCT01440712 | Completed | Drug: Gastrografin Drug: physiological serum |
Postoperative Ileus | Hospital Universitari de Bellvitge | December 2011 | Phase 4 |
| NCT00738855 | Completed | Other: Nothing per os Other: Oral Gastrografin |
Small Bowel Obstruction | Mansoura University | February 2006 | Not Applicable |
| NCT00389116 | Completed | Drug: gastrograffin Drug: water |
Small Bowel Obstruction | University Hospital, Rouen | November 2006 | Phase 4 |
| NCT01515696 | Completed | Drug: Sterile water Drug: Gastrografin |
Meconium Ileus Very Low Birth Weight Infant |
Nadja Haiden,MD | October 2007 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA